Serum measurements of testosterone, insulin-like growth factor 1, and insulin-like growth factor binding protein-3 in the diagnosis of prostate cancer among Korean men

Asian Journal of Andrology

Volumn 10, Issue 2, 2008, Pages 207-213

  Hong, Sung Kyu ^a   Han, Byung Kyu ^a   Jeong, Jae Seung ^a   Jeong, Seong Jin ^a   Moon, Ki Hyuk ^a   Byun, Seok Soo ^a   Lee, Sang Eun ^a  

^a Seoul National University Bundang Hospital   (South Korea)

Author keywords

Insulin like growth factor; Insulin like growth factor binding protein 3; Prostate; Prostate cancer; Testosterone

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TESTOSTERONE;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DISEASE ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KOREA; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE EVALUATION; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RADICAL RETROPUBIC PROSTATECTOMY; TESTOSTERONE BLOOD LEVEL;

AGED; BIOPSY, NEEDLE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; KOREA; MALE; MIDDLE AGED; PROGNOSIS; PROSTATIC NEOPLASMS; TESTOSTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 40349112698     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1111/j.1745-7262.2008.00296.x     Document Type: Article

References (20)

1. Saito T, Kitamura Y, Komatsubara S, Matsumoto Y, Sugita T, Hara N. Outcomes of locally advanced prostate cancer: A single institution study of 209 patients in Japan. Asian J Androl 2006; 8: 555-61.
2. Wu AH, Whittemore AS, Kolonel LN, John EM, Gallagher RP, West DW, et al. Serum androgens and sex hormone-binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada. Cancer Epidemiol Biomarkers Prev 1995; 4: 735-41.
3. Platz EA, Rimm EB, Willett WC, Kantoff PW, Giovannucci E. Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. J Natl Cancer Inst 2000; 92: 2009-17.
4. Iversen P, Rasmussen F, Christensen IJ. Serum testosterone as a prognostic factor in patients with advanced prostatic carcinoma. Scand J Urol Nephrol Suppl 1994; 157: 41-7.
5. Schatzl G, Madersbacher S, Thurridl T, Waldmuller J, Kramer G, Haitel A, et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate 2001; 47: 52-8.
6. Schatzl G, Madersbacher S, Haitel A, Gsur A, Preyer M, Haidinger G, et al. Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer. J Urol 2003; 169: 1312-5.
7. Zagars GK, Pollack A, von Eschenbach AC. Serum testoster-one-a significant determinant of metastatic relapse for irradiated localized prostate cancer. Urology 1997; 49: 327-34.
8. Fodstad P, Bjørro T, Torlakovic G, Fossa SD. No association of serum gonadal or pituitary hormones with prognostic parameters in stages T1 to T3 PN0M0 prostate cancer. J Urol 2002; 168: 1188-92.
9. Teloken C, Da Ros CT, Caraver F, Weber FA, Cavalheiro AP, Graziottin TM. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: Hypogonadism represents bad prognosis in prostate cancer. J Urol 2005; 174: 2178-80.
10. Imamoto T, Suzuki H, Fukasawa S, Shimbo M, Inahara M, Komiya A, et al. Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy. Eur Urol 2005; 47: 308-12.
11. Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, Adami HO. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 1997; 76: 1115-8.
12. Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M, et al. Insulin-like growth factor I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002; 94: 1099-106.
13. Oliver SE, Gunnell D, Donovan J, Peters TJ, Persad R, Gillatt D, et al. Screen-detected prostate cancer and the insulin-like growth factor axis: results of a population-based case-control study. Int J Cancer 2004; 108: 887-92.
14. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-1, IGF binding protein-3, and cancer risk: Systemic review and meta-re-gression analysis. Lancet 2004; 363: 1346-53.
15. Woodson K, Tangrea JA, Pollak M, Copeland TD, Taylor PR, Virtamo J, et al. Serum insulin-like growth factor I: Tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. Cancer Res 2003; 63: 3991-4.
16. Janssen JA, Wildhagen MF, Ito K, Blijenberg BG, Van Schaik RH, Roobol MJ, et al. Circulating free insulin-like growth factor (IGF)-I, total IGF-1, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: Results of a case-control study involving 201 patients within a population-based screening with a 4-year interval. J Clin Endocrinol Metab 2004; 89: 4391-6.
17. Finne P, Auvinen A, Koistinen H, Zhang WM, Maattanen L, Rannikko S, et al. Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen. J Clin Endocrinol Metab 2000; 85: 2744-7.
18. Ismail HA, Pollak M, Behlouli H, Tanguay S, Begin LR, Aprikian AG. Serum insulin-like growth factor (IGF)-1 and IGF-binding protein-3 do not correlate with Gleason score or quantity of prostate cancer in biopsy samples. BJU Int 2003; 92: 699-702.
19. Marszalek M, Wachter J, Ponholzer A, Leitha T, Rauchenwald M, Madersbacher S. Insulin-like growth factor 1, chromogranin A and prostate specific antigen serum levels in prostate cancer patients and controls. Eur Urol 2005; 48: 34-9.
20. Shariat SF, Lamb DJ, Kattan MW, Nguyen C, Kim J, Beck J, et al. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding pro-teins-2 and -3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol 2002; 20: 833-41.